This taken from Dow Jones Australian News. DJ Mesoblast...

This taken from Dow Jones Australian News.

DJ Mesoblast "Presentation" Merely a Poster, says Macquarie-- Market Talk.

0151 GMT ( Dow Jones)  After  biotech company Mesoblast (MSB.AU ) announced Phase II clinical trial data on its intravenous stem cell treatment for diabetes - linked kidney disease has been selected for presentation at the American Diabetes Association conference in Boston next month, Macquarie says the presentation consists of  merely a poster among more than 2000 others.  The broker has an Underperform rating on the stock. " With the vast majority of intravenously injected stem cells being trapped and cleared by the lungs before even reaching the arterial circulation, we believe any attempt to alter the course of an illness through this route of administration is likely to end in failure, particularly when the potential mechanism of action of a therapeutic is still highly theoretical," the broker says. ( [email protected]; @beckthurlow)
  ********************************************
It certainly would be good to have these comments  clarified  quickly by MSB.....

i.e. Truth or Mischief..

This release , if it is true, certainly throws a  bucket of cold water on our announcement...if , however it is untrue, then a retraction and apology  by Macquarie  should be issued immediately.